{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T06:30:15Z","timestamp":1714717815016},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00169","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T22:10:06Z","timestamp":1497651006000},"page":"1399-1408","source":"Crossref","is-referenced-by-count":4,"title":["A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice"],"prefix":"10.1248","volume":"40","author":[{"given":"Caina","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojiang","family":"Hou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuainan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Huan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongan","family":"Yu","sequence":"additional","affiliation":[{"name":"Jiangsu T-mab Biopharma Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujuan","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shousheng","family":"Yan","sequence":"additional","affiliation":[{"name":"Jiangsu T-mab Biopharma Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhufang","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Neumiller JJ. Incretin-based therapies. <i>Med. Clin. North Am.<\/i>, <b>99<\/b>, 107\u2013129 (2015).","DOI":"10.1016\/j.mcna.2014.08.013"},{"key":"2","unstructured":"2) Taguchi K, Chuang VT, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. <i>J. Pharm. Sci.<\/i>, <b>101<\/b>, 3033\u20133046 (2012)."},{"key":"3","unstructured":"3) Flisiak R, Flisiak I. Albinterferon-alpha 2b: a new treatment option for hepatitis C. <i>Expert Opin. Biol. Ther.<\/i>, <b>10<\/b>, 1509\u20131515 (2010)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. <i>Diabetes<\/i>, <b>53<\/b>, 2492\u20132500 (2004).","DOI":"10.2337\/diabetes.53.9.2492"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH, van Vliet AA. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. <i>Int. J. Clin. Pharmacol. Ther.<\/i>, <b>46<\/b>, 443\u2013452 (2008).","DOI":"10.5414\/CPP46443"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. <i>Gastroenterology<\/i>, <b>134<\/b>, 1137\u20131147 (2008).","DOI":"10.1053\/j.gastro.2008.01.017"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zhang L, Wang L, Meng ZY, Gan H, Gu RL, Wu ZN, Gao L, Zhu XX, Sun WZ, Li J, Zheng Y, Dou GF. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>445<\/b>, 511\u2013516 (2014).","DOI":"10.1016\/j.bbrc.2014.02.045"},{"key":"8","unstructured":"8) Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management for type 2 diabetes. <i>Ann. Pharmacother.<\/i>, <b>49<\/b>, 351\u2013359 (2015)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Li CN, Huan Y, Shen N, Ji LX, Sun SJ, Liu SN, Liu Q, Gao LH, Tan FL, Wang YP, Shen ZF. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>400<\/b>, 563\u2013568 (2010).","DOI":"10.1016\/j.bbrc.2010.08.103"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Chen ZY, Liu SN, Li CN, Sun SJ, Liu Q, Lei L, Gao LH, Shen ZF. Atorvastatin helps preserve \u03b2 cell function in obese C57BL\/6J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. <i>Lipids Health Dis.<\/i>, <b>13<\/b>, 98 (2014).","DOI":"10.1186\/1476-511X-13-98"},{"key":"11","unstructured":"11) Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. <i>J Diabetes Investig.<\/i>, <b>4<\/b>, 108\u2013130 (2013)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Bhavsar S, Mudaliar S, Cherrington A. Evolution of exenatide as a diabetes therapeutic. <i>Curr. Diabetes Rev.<\/i>, <b>9<\/b>, 161\u2013193 (2013).","DOI":"10.2174\/157339913805076472"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chon S, Riveline JP, Blondeau B, Gautier JF. Incretin-based therapy and pancreatic beta cells. <i>Diabetes Metab.<\/i>, <b>40<\/b>, 411\u2013422 (2014).","DOI":"10.1016\/j.diabet.2014.05.003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Boutant M, Ramos OH, Tourrel-Cuzin C, Movassat J, Ilias A, Vallois D, Planchais J, P\u00e9gorier J-P, Schuit F, Petit PX, Bossard P, Maedler K, Grapin-Botton A, Vasseur-Cognet M. COUP-TFII controls mouse pancreatic \u03b2-cell mass through GLP-1-\u03b2-catenin signaling pathways. <i>PLOS ONE<\/i>, <b>7<\/b>, e30847 (2012).","DOI":"10.1371\/journal.pone.0030847"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tschen SI, Georgia S, Dhawan S, Bhushan A. Skp2 is required for incretin hormone-mediated \u03b2-cell proliferation. <i>Mol. Endocrinol.<\/i>, <b>25<\/b>, 2134\u20132143 (2011).","DOI":"10.1210\/me.2011-1119"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Bastien-Dionne PO, Valenti L, Kon N, Gu W, Buteau J. Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic \u03b2-cell mass expansion. <i>Diabetes<\/i>, <b>60<\/b>, 3217\u20133222 (2011).","DOI":"10.2337\/db11-0101"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Liu Z, Stanojevic V, Avadhani S, Yano T, Habener JF. Stromal cell-derived factor-1 (SDF-1)\/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. <i>Diabetologia<\/i>, <b>54<\/b>, 2067\u20132076 (2011).","DOI":"10.1007\/s00125-011-2181-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, Soderman A, Spinka-Doms T, Stojanovic-Susulic V, Thomas BA, O\u2019Neil KT. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. <i>Diabetes<\/i>, <b>57<\/b>, 1926\u20131934 (2008).","DOI":"10.2337\/db07-1775"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Parlevliet ET, Schr\u00f6der-van der Elst JP, Corssmit EP, Picha K, O\u2019Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>328<\/b>, 240\u2013248 (2009).","DOI":"10.1124\/jpet.108.144154"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Schnabel CA, Fineberg SE, Kim DD. Immunogenicity of xenopeptide hormone therapies. <i>Peptides<\/i>, <b>27<\/b>, 1902\u20131910 (2006).","DOI":"10.1016\/j.peptides.2006.01.019"},{"key":"21","unstructured":"21) Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. <i>Diabetes Obes. Metab.<\/i>, <b>14<\/b>, 546\u2013554 (2012)."},{"key":"22","unstructured":"22) Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videb\u00e6k N, Holst H, Nauck M. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>96<\/b>, 1695\u20131702 (2011)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Milicevic Z, Anglin G, Harper K, Konrad RJ, Skrivanek Z, Glaesner W, Karanikas CA, Mace K. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. <i>Diabetes Obes. Metab.<\/i>, <b>18<\/b>, 533\u2013536 (2016).","DOI":"10.1111\/dom.12640"}],"container-title":["Biological &amp; Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/9\/40_b17-00169\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T06:43:39Z","timestamp":1569480219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/9\/40_b17-00169\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00169","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}